The Allegretti Lab

Our @BrighamGI @AllegrettiLab study comparing 1-year effectiveness of tofa vs uste for #UC is out in @IBDJournals: doi-org.ezp-prod1.hul.harvard.edu/10.1093/ibd/iz… 🔑After adjusting for confounders, no difference in steroid-free remission at 12 or 52 wks 🔑Similar drug survival during follow-up

Higher steroid free remission on ups than on uste in a real word cohort per @RahulSDalalMD @EdBarnesMD @DrJessicaA

Thank you @DrAllegrettiIBD! Some 🔑 pts: ⭐️Tramadol a/w ⬇️ odds of infection, SBO, and mortality vs traditional opioids in IBD, though there may be residual confounding. ⭐️Rx these cautiously and only when necessary! Treat the IBD. ⭐️ More 🔬 is needed comparing analgesics.

Check out our data on utilizing colonic washes to identify c.difficile colonization in #IBD patients undergoing colonoscopy @AllegrettiLab #DDW2023

@AllegrettiLab super star @RahulSDalalMD presenting data on real world outcomes of comparative effectiveness for #IBD therapies. #DDW2023

Congratulations to our 1️⃣4️⃣ faculty named Top Doctors 2023 by @BostonMagazine! #TopDocs⚕️ Thank you to our dedicated #BrighamGIFaculty for their passion & commitment to providing top-notch & cutting-edge care in digestive & liver health to our patients🩺 bostonmagazine.com/find-a-doctor/…

Congratulations to our Medical Director of Crohn's and Colitis Center & Director of Clinical Research Dr. Jessica Allegretti (@DrJessicaA) for her #promotion to Associate Professor at Harvard Medical School @harvardmed 🎉 #BWHIBD #BrighamGIFaculty #BrighamGIAlum @AllegrettiLab

@DrJessicaA @RahulSDalalMD @BrighamGI Congrats @RahulSDalalMD !

Right now @RahulSDalalMD our ⭐️ #IBD fellow is presenting our data on ustekinumab vs tofacitinib at #ACG2022 @BrighamGI

Our RCT➡️⬇️#alcohol drinking post #FMT in #cirrhosis pubmed.ncbi.nlm.nih.gov/32750174 Question Are #microbiota enough for this ? YES! Stools, but🚫supernatants from pts post #FMT ⬇️drinking in GF mice thru #SCFA ⬆️#intestine RNAseq changes>>liver or brain Read⤵️ rdcu.be/cXTxo

@BrighamGI @DrJessicaA @BrighamWomens @ShermanPrize @AllegrettiLab @harvardmed @CrohnsColitisFn Congrats, Jess!

So thrilled our data on the potential role of BAs as novel #biomarkers for #CDI recurrence is out! Thank you @AmCollegeGastro for funding this work. And big thanks to @bhmullish and @imperialcollege for getting us to the finish line! bit.ly/3S8Yda2

Join Us! BWH is accepting applications for 2023-24 Advanced IBD Fellowship. 1-year, comprehensive training program and includes opportunities for coursework at the Harvard School of Public Health. Direct inquiries to PD Matthew Hamilton MD mjhamilton@bwh.harvard.edu. Q's ⬇️

Study from #BrighamIBDFellow @RahulSDalalMD @AllegrettiLab on long-term outcomes after #ustekinumab dose⬆️ for #IBD 🔑>50% in corticosteroid-free remission (CFCR) after 12mo 🔑≥40% in CFCR after 24mo 🔑43% CD & 55% UC pts in endo remission @IBDJournals: doi.org/10.1093/ibd/iz…

Data re: #tofacitinib for #pouchitis and related disorders are lacking. We @AllegrettiLab @BrighamGI published our single center experience in @IBDJournals : Tofacitinib for the Treatment of Pouch-Related Disorders: A Case Series academic.oup.com/ibdjournal/adv…

@AllegrettiLab @PDulaiMD @CSTseMD #AdamChiefetz #KostasPapamichael @DrPhil_Gu @GIDocAnnie @jensemineriomd @AmyLightnerMD @IBDMD @RishikaChughMD @JillGaidosMD @SimonHongMD @ps46bronx @JHashashMD @FarrayeIBD #JoelRoshMD

Congratulations to 3rd-yr #BrighamGIFellow @RahulSDalalMD on graduating w/ his Master of Public Health degree from @HarvardChanSPH 👨‍🎓🎉🎓 We are so proud of you & look forward to your continued success as a clinical investigator! #HarvardChan22 #Harvard22 #MDMPH @AllegrettiLab

It was a great meet up with friends @EdwardLoftus2 @IBD_Houston @tinahamd @DrJessicaA at #DDW2022 @AmerGastroAssn @DDWMeeting

@DrJessicaA of @BrighamGI discusses her trial of an oral #microbiome therapeutic that effectively reduces recurrent #Cdiff @DDWMeeting #DDW2022 @AllegrettiLab

@ACG Eastern Regional meeting chaired by @DrJessicaA and Dr. Sita Chokhavatia off to a great start. Lots of great #womeninGI representation

EBGI: Infliximab Therapy Is Associated w/ Reduced Antibody Responses Against SARS-CoV-2 Reviewers: Dr. Rahul Dalal & Dr. Jessica Allegretti 🟣 Read: bit.ly/3JgFuWz @DrJessicaA @JenKolbMD @KumarShria @PhilipOkaforMD @spaulliver @JosephHabibi_MD @swatigp @RahulSDalalMD